Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

Pfizer Inc. ($PFE) is returning to the U.S. debt markets with a fresh corporate bond offering aimed at raising at least $5 ...

Pfizer enters the lucrative weight-loss drug market with a massive $10 billion Metsera acquisition, targeting a $150-200 ...

Pfizer rises after a study found that the company's new mRNA flu vaccine outperforms traditional shots against predominant strains.

On Oct. 3, students and employees in Middlesex Community College’s STEM (science, technology, engineering, mathematics) ...

There’s room for more than one winner in this race for GLP-1 weight loss supremacy, but some of these winners are going to be ...

Pfizer Inc. and Tris Pharma Inc. will pay the state of Texas $41.5 million to settle claims that it allegedly provided ...

Pfizer Inc. is looking to sell its remaining stake in Covid-19 vaccine partner BioNTech SE, a remnant from one of the pandemic’s most lucrative collaborations.

Pfizer beats Q3 estimates, raises FY guidance, acquires Metsera for obesity drugs, and offers a 7% yield. Read here for an ...

Pfizer noted it has completed its acquisition of all outstanding shares of the company’s common stock for $65.60 per share in ...

Pfizer Inc. (NYSE: PFE) today announced the successful completion of its acquisition of Metsera, Inc. (NASDAQ: MTSR), a ...

Pfizer is buying its way back into the obesity-drug game after fighting off a rival bid from Novo Nordisk to buy Metsera, ...